The therapeutic options for liver metastases of colorectal cancer mainly include surgical resection and palliative chemotherapy. More recently, the increased availability of new and more active cytotoxic drugs has increased the appeal of a combined treatment strategy, in which chemotherapy is administered before surgery. However, the efficacy of neoadjuvant chemotherapy of CRC liver metastases is limited by: (1) the persistence of micro metastatic foci that cannot be seen by conventional imaging techniques, placed either in other sites throughout the liver and/or in the site of the previous macroscopic metastasis that has undergone to clinical complete response; (2) the occurrence of escape mechanisms. The molecular basis regulating these processes are described and the first clinical attempts to overcome these mechanisms through the use of target-based agents are also reported. Finally, biological rationales to optimize the activity of these agents in neoadjuvant setting are discussed.
|Titolo:||Target-based agents in neoadjuvant treatment of liver metastases from colorectal cancer : secret weapons in anti-cancer war?|
|Parole Chiave:||Angiogenesis; Colorectal cancer; Liver metastases; Neoadjuvant therapy; Target-based agents|
|Settore Scientifico Disciplinare:||Settore MED/13 - Endocrinologia|
|Data di pubblicazione:||2009|
|Digital Object Identifier (DOI):||10.4161/cbt.8.18.9600|
|Appare nelle tipologie:||01 - Articolo su periodico|